# Therasid Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therasid-bioscience

- Industry: Biotechnology
- Headquarters: Gyeonggi-do, South Korea
- Website: www.therasidbio.com
- Total disclosed funding: $5.1M
- Latest round: Series A (Jun 17, 2019)
- Investors on record: 3

## About

Based in Gyeonggi-do, South Korea and founded in 2017, Therasid Bioscience operates as a biotechnology company that focuses on the development of drugs for the treatment of non-alcoholic steatohepatitis. In June 2018, the company raised an undisclosed amount in angel funding. In June 2019, the company raised KRW 6 billion in series A funding.

The company'NASH platform is based on hepatocyte, Kupffer cell and hepatic stellate cell which are representative of liver cells. The company has the diverse NASH pipelines ranging from earyl stage to clinical stage. The pipelines include TB-840, TB-RB, TB-DK, TB-IH, which can provide an opportunity to develop the combination therapy for NASH.

## Funding rounds

- Series A, Jun 17, 2019, $5.1M — AJU IB Investment, G.N.TECH Venture Capital, BSK Investment

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- G.N.TECH Venture Capital (https://capitalatlas.ai/funds/g-n-tech-venture-capital) — Series A
- BSK Investment (https://capitalatlas.ai/funds/bsk-investment) — Series A